Clinical trials: Osteoporosis Postmenopausal
Osteoporosis, Postmenopausal
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
- Trial name
- NCT00557310
- Testing
- teriparatide
- Where
- 6 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
This study will evaluate the effect of a 1-year administration of the vitamin D analog 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density (BMD), safety, and tolerability.
- Trial name
- 2MD-3H-2B (NCT00715676)
- Testing
- DP001
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Deltanoid Pharmaceuticals
Osteoporosis
A Phase I Study of AK159 in Healthy Postmenopausal Women
The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.
- Trial name
- NCT01935479
- Testing
- AK159, MN-10-T
- Where
- 3 sites in Japan
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Asahi Kasei Therapeutics Corporation
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
This 3 arm study will evaluate renal safety after administration of an intravenous (iv) injection or infusion of Bonviva, compared to oral alendronate, in patients with postmenopausal osteoporosis, at increased risk of renal…
- Trial name
- NCT00503113
- Testing
- ibandronate [Bonviva/Boniva], Alendronate
- Where
- 44 sites in United States, Argentina and 4 more
- Volunteers
- 801 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic efficacy of MK0773 in healthy postmenopausal women.
- Trial name
- NCT01011725
- Testing
- MK 0773
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postmenopausal Osteoporosis
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.
- Trial name
- VERO (NCT01709110)
- Testing
- Teriparatide, Risedronate, Calcium
- Where
- 103 sites in United States, Argentina and 13 more
- Volunteers
- 1,366 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Women With Primary Osteoporosis
STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)
The primary objective of the study is to explore the relationship between a new image technology (ImaTx), that analyzes the trabecular structure of the bone using digitized radiographs and the bone mineral density (BMD) measured…
- Trial name
- NCT00583518
- Testing
- Parathyroid hormone (PTH)
- Where
- Denmark
- Volunteers
- 129 people
- Sponsor
- Nycomed
Post-menopausal Osteoporosis
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
- Trial name
- NCT00718861
- Testing
- Zoledronic acid
- Where
- 57 sites in United States, Argentina and 16 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal…
- Trial name
- NCT00790101
- Testing
- Risedronate, Raloxifene
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sanofi
Osteoporosis, Postmenopausal
Comparative Efficacy, Safety, PK, and Immunogenicity Study
this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women…
- Trial name
- NCT05853354
- Testing
- Denosumab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 392 people
- Sponsor
- Luye Pharma Group Ltd.
Osteoporosis
To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women.
- Trial name
- NCT00651534
- Testing
- Ronacaleret
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women
The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for the prevention of osteoporosis.
- Trial name
- PH3 (NCT00693667)
- Testing
- PH3
- Where
- Taiwan
- Volunteers
- 92 people
- Sponsor
- PhytoHealth Corporation
Osteoporosis
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
The purpose of this study is to assess to what extent sequential treatment with odanacatib results in incremental gains in bone mineral density (BMD) over time in female participants who have received at least 3 years of…
- Trial name
- NCT01803607
- Testing
- odanacatib
- Volunteers
- 135 people
- Sponsor
- Merck Sharp & Dohme LLC
Postmenopausal Women With Osteoporosis
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.
- Trial name
- ARCH (NCT01631214)
- Testing
- Romosozumab, Alendronate
- Where
- 316 sites in United States, Argentina and 40 more
- Volunteers
- 4,093 people
- Sponsor
- Amgen
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550…
- Trial name
- NCT00551174
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 781 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis
The purpose of this study is to evaluate the effects of teriparatide on skeleton images in postmenopausal women with osteoporosis. Teriparatide is a bone formation agent that stimulates the production of new bone in the skeleton.
- Trial name
- NCT00259298
- Testing
- teriparatide
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
Study of Investigational Drug in Osteoporosis (MK-0217-908)
The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis.
- Trial name
- NCT00092053
- Testing
- ibandronate
- Volunteers
- 203 people
- Sponsor
- Organon and Co
Osteopenia, Osteoporosis
Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD
This study is being conducted to compare the effect of increasing nasal teriparatide dosing on percent change in Bone Mineral Density (BMD) of the lumbar spine after 24 weeks of therapy in postmenopausal women with low bone…
- Trial name
- NCT00624481
- Testing
- Teriparatide, Teriparatide Nasal Spray
- Volunteers
- 350 people
- Sponsor
- Nastech Pharmaceutical Company, Inc.
Menopause, Osteoporosis
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal…
- Trial name
- NCT00808132
- Testing
- bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg
- Where
- 178 sites in United States, Argentina and 10 more
- Volunteers
- 1,886 people
- Sponsor
- Pfizer
Postmenopausal Osteoporosis
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
This study is designed to provide information about the bone anabolic properties and absorption profile of Unigene's PTH Analog when administered as oral tablets over a period of 24 weeks to postmenopausal women with osteoporosis.
- Trial name
- NCT01321723
- Testing
- PTH analog, Forsteo (Teriparatide)
- Where
- 4 sites in Denmark, Estonia
- Volunteers
- 97 people
- Sponsor
- Unigene Laboratories Inc.